Post-renal transplant hemolytic uremic syndrome following combination therapy with tacrolimus and everolimus.
A 34-year old male renal transplant recipient developed thrombotic microangiopathy (Hemolytic Uremic Syndrome) in the early post-transplant period following combined immuno-suppressive therapy with tacrolimus and everolimus. The management consisted of discontinuation of tacrolimus and substitution with mycophenolate mofetil. His renal functions improved, the hematological abnormalities reversed and he continues to have good graft function one year later.
Pratap
Balaji
B
Sri Ramachandra Medical College and Research Institute, Chennai, India.
Abraham
Georgi
G
Srinivas
C N
CN
Bhaskar
Shanmuga
S
D000328:Adult; D001706:Biopsy; D004359:Drug Therapy, Combination; D000068338:Everolimus; D006084:Graft Rejection / Q000188:drug therapy* / Q000473:pathology; D006463:Hemolytic-Uremic Syndrome / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects* / Q000627:therapeutic use; D016030:Kidney Transplantation; D008297:Male; D009173:Mycophenolic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D011355:Prodrugs; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D016559:Tacrolimus / Q000009:adverse effects* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D011355:Prodrugs; D000068338:Everolimus; D009173:Mycophenolic Acid; D020123:Sirolimus; D016559:Tacrolimus